CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $865M, above the global median of $548.88M
- FinancialsAltman Z-Score 1.93: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
783.88MUSDvs all stocks (USD)
Trailing P/E
34.81xvs Medical Devices peers
Revenue (TTM)
865.00MUSDvs all stocks (USD)
Profit Margin
2.56%vs Medical Devices peers
Beta
0.9620xvs all stocks
52-Week Change
52.31%vs all stocks
Market Capitalization
783.88MUSDvs all stocks (USD)
Enterprise Value
1.07BUSDvs all stocks (USD)
Trailing P/E
34.81xvs Medical Devices peers
Forward P/E
17.24xvs Medical Devices peers
PEG Ratio
-0.2970xvs Medical Devices peers
Price to Sales (TTM)
0.9057xvs Medical Devices peers
Price to Book (MRQ)
1.57xvs Medical Devices peers
Enterprise to Revenue
1.24xvs Medical Devices peers
Enterprise to EBITDA
10.75xvs Medical Devices peers
Gross Margin
36.44%vs Medical Devices peers
Profit Margin
2.56%vs Medical Devices peers
Operating Margin
10.83%vs Medical Devices peers
Return on Assets (TTM)
4.15%vs Medical Devices peers
Return on Equity (TTM)
4.59%vs Medical Devices peers
Revenue (TTM)
865.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
20.63USDUpdated Sep 28, 2026Quarterly Revenue Growth
3.70%vs Medical Devices peers
Gross Profit (TTM)
296.90MUSDvs all stocks (USD)
EBITDA (TTM)
95.30MUSDvs all stocks (USD)
Net Income (TTM)
22.10MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
11.30MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-39.52MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Minority Interest (Equity)
14.00MUSDFY2025 · Sep 30, 2025Revenue
844.60MUSDFY2025 · Sep 30, 2025Cost of Goods Sold
554.10MUSDFY2025 · Sep 30, 2025Gross Profit
290.50MUSDFY2025 · Sep 30, 2025Operating Income
66.10MUSDvs all stocks (USD)
Pre-tax Income
-59.20MUSDFY2025 · Sep 30, 2025Income Tax Expense
10.70MUSDFY2025 · Sep 30, 2025Net Income
-69.90MUSDFY2025 · Sep 30, 2025EBIT
-26.50MUSDFY2025 · Sep 30, 2025EBITDA (Income Statement)
97.60MUSDFY2025 · Sep 30, 2025Research & Development
91.10MUSDFY2025 · Sep 30, 2025Selling, General & Administrative
133.30MUSDFY2025 · Sep 30, 2025Non-operating Interest Income
8.50MUSDFY2025 · Sep 30, 2025Non-operating Interest Expense
32.70MUSDFY2025 · Sep 30, 2025EPS (Basic)
-1.70USDFY2025 · Sep 30, 2025EPS (Diluted)
-1.70USDFY2025 · Sep 30, 2025Basic Shares Outstanding
41.40MSharesFY2025 · Sep 30, 2025Diluted Shares Outstanding
41.40MSharesFY2025 · Sep 30, 2025Net Income from Continuing Operations
-69.90MUSDFY2025 · Sep 30, 2025Minority Interests (P&L)
-400.00KUSDFY2025 · Sep 30, 2025Operating Cash Flow
-55.20MUSDFY2025 · Sep 30, 2025Free Cash Flow
-78.10MUSDFY2025 · Sep 30, 2025Cash & Cash Equivalents (End of Period)
147.10MUSDFY2025 · Sep 30, 2025Income Tax Paid
18.60MUSDFY2025 · Sep 30, 2025Interest Paid
31.30MUSDFY2025 · Sep 30, 2025Starting Profit (CF Statement)
-69.90MUSDFY2025 · Sep 30, 2025Depreciation & Amortization
27.20MUSDFY2025 · Sep 30, 2025Deferred Taxes (CF)
-500.00KUSDFY2025 · Sep 30, 2025Stock-based Compensation
15.00MUSDFY2025 · Sep 30, 2025Other Non-cash Items
900.00KUSDFY2025 · Sep 30, 2025Change in Accounts Receivable (CF)
100.00KUSDFY2025 · Sep 30, 2025Change in Accounts Payable (CF)
6.20MUSDFY2025 · Sep 30, 2025Change in Other Assets/Liabilities
-34.20MUSDFY2025 · Sep 30, 2025Capital Expenditures
-22.90MUSDFY2025 · Sep 30, 2025Net Acquisitions
0.00USDFY2025 · Sep 30, 2025Purchase of Investments
-31.40MUSDFY2025 · Sep 30, 2025Sale of Investments
65.40MUSDFY2025 · Sep 30, 2025Other Investing Activity
-800.00KUSDFY2025 · Sep 30, 2025Net Investing Cash Flow
10.30MUSDFY2025 · Sep 30, 2025Long-term Debt Issuance
126.90MUSDFY2025 · Sep 30, 2025Long-term Debt Payments
-201.90MUSDFY2025 · Sep 30, 2025Other Financing Charges
-4.20MUSDFY2025 · Sep 30, 2025Net Financing Cash Flow
-79.20MUSDFY2025 · Sep 30, 2025Shares Outstanding
42.15MSharesUpdated Sep 28, 2026Float Shares
41.37MSharesUpdated Sep 28, 2026Shares Short
1.41MSharesUpdated Sep 28, 2026Short Ratio
1.84daysvs all stocks
Short % of Shares Outstanding
3.77%vs all stocks
% Held by Insiders
1.71%vs all stocks
% Held by Institutions
98.58%vs all stocks
Total Cash (MRQ)
100.10MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.38USDUpdated Sep 28, 2026Total Debt (MRQ)
379.30MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.7430xvs Medical Devices peers
Current Ratio (MRQ)
3.38xvs Medical Devices peers
Book Value per Share (MRQ)
11.78USDUpdated Sep 28, 2026Total Assets
1.11BUSDvs all stocks (USD)
Total Current Assets
641.80MUSDFY2025 · Sep 30, 2025Total Liabilities
620.80MUSDFY2025 · Sep 30, 2025Total Non-current Assets
465.60MUSDFY2025 · Sep 30, 2025Total Non-current Liabilities
433.60MUSDFY2025 · Sep 30, 2025Total Current Liabilities
187.20MUSDFY2025 · Sep 30, 2025Cash & Cash Equivalents
145.00MUSDFY2025 · Sep 30, 2025Other Short-term Investments
10.10MUSDFY2025 · Sep 30, 2025Accounts Receivable
156.60MUSDFY2025 · Sep 30, 2025Inventory
299.40MUSDFY2025 · Sep 30, 2025Accounts Payable
69.90MUSDFY2025 · Sep 30, 2025Short-term Debt
5.90MUSDFY2025 · Sep 30, 2025Deferred Revenue
13.00MUSDFY2025 · Sep 30, 2025Other Current Liabilities
20.00MUSDFY2025 · Sep 30, 2025Long-term Debt
390.00MUSDFY2025 · Sep 30, 2025Other Non-current Liabilities
29.60MUSDFY2025 · Sep 30, 2025Common Stock (Book)
400.00KUSDFY2025 · Sep 30, 2025Retained Earnings
-5.90MUSDFY2025 · Sep 30, 2025Total Shareholders' Equity
486.60MUSDvs all stocks (USD)
52-Week Low
9.09USDUpdated Sep 28, 202652-Week High
18.63USDUpdated Sep 28, 202652-Week Change
52.31%vs all stocks
Beta
0.9620xvs all stocks
50-Day MA
16.19USDUpdated Sep 28, 2026200-Day MA
12.83USDUpdated Sep 28, 2026Avg 10-Day Volume
632.46KSharesUpdated Sep 28, 2026Avg 30-Day Volume
732.24KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
0.5300USDUpdated Sep 28, 2026Other Income / Expense
-98.30MUSDFY2025 · Sep 30, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 1.93: grey zoneSignificant
Altman Z-Score: 1.93
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $865M, above the global median of $548.88MNotable
Revenue (USD): 865,000,000Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
Immix Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hunan Jiudian Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gyre Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pharming Group N.V.
Tier 1ProductionApproval-Gated PipelineRule
Teyi Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tibet Duorui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule